
A First for Rett: FDA Approves Trofinetide for Treatment of Rett Syndrome!
Friday, March 10, 2023
This first-ever treatment is approved for individuals with Rett syndrome. (Updated March 19, 2023) Today, March 10, 2023, Acadia Pharmaceuticals announced that their investigational drug, Trofinetide, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of Rett syndrome. The drug, marketed under the name DAYBUE™, is expected to be commercially … Read More